Daniel L. Menichella is Sr. VP & Business Development at Talecris Biotherapeutics Holdings Corp. (TLCR). They have made 3 open-market trades across 2 companies since 2010, most recently 2021-02-08.
CIK 0001472131
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $230K since 2021, against 2 sales. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.